Incidence of Hyperhomocysteinemia and Mthfr C677T Polymorphism Among Young Patients with Acute Myocardial Infarction

• Published in: Journal of medical biochemistry Vol. 28; no. 1; pp. 41 - 45
• Main Authors: Beletic, Andelo, Mirkovic, Dusko, Antonijevic, Nebojsa, Dordevic, Valentina, Sango, Violeta, Jakovljevic, Branko, Perunicic, Jovan, Ilic, Mirka, Vasiljevic, Zorana, Majkic-Singh, Nada
• Format: Journal Article
• Language: English
• Published: Belgrade Versita 01.01.2009; Society of Medical Biochemists of Serbia; Society of Medical Biochemists of Serbia, Belgrade
• Subjects: hiperhomocisteinemija; hyperhomocysteinemia; infarkt miokarda; mladi bolesnici; MTHFR; myocardial infarction; young adults
• ISSN: 1452-8258; 1452-8266
• DOI: 10.2478/v10011-008-0029-9

Hyperhomocysteinemia is considered an independent risk factor for premature cardiovascular disease. Mutation MTHFR C677T reduces the activity of methylenetetra-hydrofolatereductase and may cause hyperhomocysteinemia. Incidence of hyperhomocysteinemia (homocysteine above 12 μmol/L), homocysteine level, and distribution of MTHFR C677T genotypes (C/C, C/T and T/T) are compared between young patients with acute myocardial infarction and healthy persons, matched by age. Study involved 86 patients younger than 45 years (77 men and 9 women) and 35 controls. Homocysteine was measured by an HPLC method and the MTHFR C677T genotype determined using PCR amplification and digestion with Hinf I. Statistical analyses included chisquare and Mann-Whitney U tests. Hyperhomocysteinemia was present in 32.6% patients and 14.3% controls, revealing a significant difference (P= 0.038). Median homocysteine levels in patients (10.4 μmol/L) and controls (9.6 μmol/L) were significantly different (P=0.035). Among patients, 50.0% had C/C, 41.9% C/T and 8.1% T/T genotype, and the genotype had no influence on hyperhomocysteinemia incidence and homocysteine level. Genotype distribution in patients was not significantly different from that observed in controls. The conclusion is that young patients with acute myocardial infarction have higher incidence of hyperhomocysteinemia and higher homocysteine levels than healthy young adults, while there is no significant difference in the distribution of MTHFR C677T genotypes. Hiperhomocisteinemija se smatra nezavisnim faktorom rizika za preuranjeni razvoj kardiovaskularnih bolesti. Mutacija MTHFR C677T snižava aktivnost metilentetra-hidrofolatreduktaze i može dovesti do hiperhomocisteinemije. Incidenca hiperhomocisteinemije (homocisteinemija iznad 12 μmol/L), nivo homocisteina i raspodela MTHFR 677 genotipova (C/C, C/T, T/T) upoređeni su između mladih bolesnika sa akutnim infarktom miokarda i zdravih osoba iste dobi. Studija je obuhvatila 86 bolesnika mlađih od 45 godina (77 muškaraca i 9 žena) i kontrolnu grupu od 35 osoba. Homocistein je određivan metodom HPLC, a MTHFR 677 genotip PCR amplifikacijom i digestijom sa Hinf I. Podaci su statistički obrađeni pomoću Chi-square i Mann-Whitney U testa. Hiperhomocisteinemija je bila prisutna kod 32,6% bolesnika i 14,3% zdravih osoba, što predstavlja statistički značajnu razliku (P=0,038). Medijane homocisteinemija bolesnika (10,4 μmol/L) i zdravih osoba (9,6 μmol/L) bile su statistički značajno različite (P= 0,035). Raspodela MTHFR 677 genotipova kod bolesnika (50,0% C/C, 41,9% C/T i 8,1% T/T) nije se statistički značajno razlikovala od raspodele u kontrolnoj grupi. Genotip MTHFR 677 nije uticao na incidencu hiperhomocisteinemije i nivo homocisteina kod bolesnika. Može se zaključiti da mladi bolesnici sa akutnim infarktom miokarda imaju višu incidencu hiperhomocisteinemije i viši nivo homocisteina nego zdrave osobe iste starosti, pri čemu nema značajne razlike u raspodeli genotipova MTHFR.